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Summary 
A method is described for the identification of type A and type B isolates of 
Epstein-Barr virus (EBV) by means of the polymerase chain reaction. The use of 
three pairs of primers specific for genomic sequences coding for the two forms 
of EBV nuclear antigen (EBNA), 2A and 2B, and for a DNA sequence from the 
BamZ/BamR region allows the reliable and rapid detection of type A and B viruses 
in as little as 1000 EBV positive cells. 
Epstein-Barr virus (EBV), type A and B; Epstein-Barr virus nuclear antigen 
(EBNA) 2A and 2B; Polymerase chain reaction 
Two types, A and B, of Epstein-Barr virus (EBV) have been identified which 
show DNA sequence divergence within the BamHI WYH region of the genome. 
This region encodes for the Epstein-Barr nuclear antigen 2 (EBNA 2) which 
accordingly exists as two antigenically different alleles, EBNA 2A and EBNA 
2B. Recently, Rowe et al. (1989) showed that the distinction between the two 
types extends beyond the EBNA 2 gene to the EBNA 3 family of proteins. 
Whereas type B virus was previously found mainly in equatorial Africa (Zimber 
et al., 1986) recent findings indicate that this type is also widespread in other 
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regions (Sculley et al., 1988; Sixbey et al., 1989). However, type A and type 
B isolates differ in their biological properties as type B virus has a markedly 
reduced ability to transform B lymphocytes (Rickinson et al., 1987) and seems 
to show a different tissue tropism (Sixbey et al., 1989); so far, however, it is 
unknown whether these two types also possess a different pathogenic potential. 
Identification of type A and type B isolates is usually accomplished by Southern 
blot analysis of viral DNA (Zimber et al., 1986; Sixbey et al., 1989) or by 
immunoblotting of lysates of EBV infected cells with specific antisera (Rickinson 
et al., 1987). In this paper we are presenting a method of typing EBV by PCR 
using EBNA 2A and 2B gene specific primer pairs. 
Specific primers were synthesized based on the published DNA sequences of 
Dambaugh et al. (1984) (for EBNA 2A and 2B genes), and of Baer et al. (1984) 
(for the BamZ and BamR regions). 
Sequences of primers (location in the EBV genome): 
2A-FS: 5’ TCT TGA TAG GGA TCC GCT AGG ATA 3’ (1842-1865) 
2A-CS: 5’ ACC GTG GTT CTG GAC TAT CTG GAT C 3’ (2338-2314) 
2B-FS: 5’ ACT GGA TAT GAA TCC CCT GGG CAG 3’ (1769-1792) 
2B-CS: 5’ GAG TCC TGT ACT ATC AGA ACT ACA ATG 3’ (2234-2208) 
Z-FS: 5’ AAT AGA CAG CCC AGT TGA AA 3’ (103386-103405) 
Z-CS: 5’ GCA GTG CCA TAT CTG ACG TG 3’ (103894-103875) 
Cells were suspended (at 5 x lo5 cells/ml) in lysis buffer containing 100 &ml 
of freshly added proteinase K, 0.5% (w/v) NP-40, 50 mM KCl, 10 mM Tris-HCl, 
pH 8.3, 1.5 mM MgC12 (Kawasaki, 1990). Samples were incubated for 45 min 
at 56°C then heated to 95OC for 10 min; 20 ~1 were used per assay. 
Amplification conditions (in 50 ~1 assays) were: Taq polymerase (Perkin 
Elmer Cetus, Uberlingen, F.R.G.) 1.25 U/assay; dNTPs (Boehringer, Mannheim, 
F.R.G.) 200 PM (each); primer 0.1 PM; KC1 50 mM, Tris-HCl 10 mM, pH 8.3, 
MgC12 1.5 mM, gelatin 0.1% (w/v). Samples were processed for 50 cycles in 
a Bio-Med reaction cycler (Bio-Med, Theres, ERG) with denaturation at 94°C 
for 30 set, annealing at 55°C for 1 min, extension at 72°C for 3 min. Amplified 
sequences were visualized on a 2% agarose gel using standard conditions. 
Fig. 1 shows the EBV type B containing cell line AG876, the type A line 
B95-8 and the EBV negative line BJAB tested for the presence of EBNA 2A 
and EBNA 2B sequences. A control reaction was performed with a primer pair 
(Z) derived from a highly conserved region in the BamZ and BamR segments 
of the EBV genome. Strong signals were seen indicating the presence of the 
amplified EBNA 2A gene sequence of 497 bp or the EBNA 2B sequence (466 
bp) exclusively in the type A or type B infected cells, respectively. As expected, 
both cell lines were found positive for the Z/R sequence. Visible bands were 
still observed even when only one tenth of the cellular material (an equivalent 
of 1000 cells per assay) was analysed (not shown). Testing several EBV positive 
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Fig. 1. PCR typing of EBV transformed cell lines for the presence of type A and type B isolates of 
EBV. EBNA 2A and EBNA 2B gene specific sequences were amplified by using primer pairs 2A 
and 2B, respectively; primer pair Z allows the amplification of a conserved sequence common to all 
EBV strains. 1, B95-8 (typ A positive cell line); 2, AG876 (type B positive cell line); 3, BJAB (EBV 
negative cell line); 0, reagent control (without added templates); M, length standards. 
cell lines, all reacting with the Z primers, we found the type B positive cell line 
Jijoye reactive only with the 2B primers, six EBV transformed lymphoblastoid 
cell lines established from healthy EBV positive donors showed exclusively the 
2A sequence, whereas the P3HR-1 line lacking the EBNA 2 gene was negative 
for both. Thus, the method described allows the reliable and rapid detection of 
type A and B viruses in as little as 1000 cells. 
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